Clinical Research

Mass Spectrometric Immunoassay (MSIA)

SimulTOF Systems is engaged in biomarker discovery and clinical research assay development though a collaboration with the Laboratory of Dr. Randall Nelson (The Biodesign Institute, Arizona State University, Tempe, AZ.).   Current initiatives are aimed at leveraging the high-performance and speed of SimulTOF Systems MALDI-TOF mass spectrometers with the immune-affinity purification array technology developed at Arizona State University.

The analyte selectivity and parallel sample processing offered by immune-affinity purification arrays coupled with the speed, sensitivity and accuracy (over a broad mass range) offered by SimulTOF Systems mass spectrometers, will enable large-scale research investigations designed to more fully understand the distribution and characteristics of full-length proteins in relation to health and disease.

 

Presentations related to this topic

  1. Mass Spec Immunoassay - Nelson, Krone, Bieber, Williams - Anal Chem 1995, 67(7) p. 1153-1158
  2. Full-Length Characterization of Proteins in Human Populations - Borges, Rehder, Jarvis, Schaab, Oran, Nelson - Clinical Chemistry 2009, 56:2
  3. MALDI Takes the Clinical Stage - Matthew Dublin - genomeweb.com March 2012